M
Myles B.C. Dillon
Researcher at La Jolla Institute for Allergy and Immunology
Publications - 24
Citations - 2199
Myles B.C. Dillon is an academic researcher from La Jolla Institute for Allergy and Immunology. The author has contributed to research in topics: Epitope & Antigen. The author has an hindex of 13, co-authored 19 publications receiving 1804 citations. Previous affiliations of Myles B.C. Dillon include Scripps Research Institute.
Papers
More filters
Journal ArticleDOI
T cells from patients with Parkinson’s disease recognize α-synuclein peptides
David Sulzer,Roy N. Alcalay,Francesca Garretti,Lucien J. Cote,Ellen Kanter,Julian Agin-Liebes,Christopher Liong,Curtis McMurtrey,William H. Hildebrand,Xiaobo Mao,Valina L. Dawson,Ted M. Dawson,Carla Oseroff,John Pham,John Sidney,Myles B.C. Dillon,Chelsea Carpenter,Daniela Weiskopf,Elizabeth J. Phillips,Elizabeth J. Phillips,Simon Mallal,Simon Mallal,Bjoern Peters,April Frazier,Cecilia S. Lindestam Arlehamn,Alessandro Sette +25 more
TL;DR: It is shown that a defined set of peptides that are derived from α-synuclein, a protein aggregated in Parkinson’s disease, act as antigenic epitopes displayed by these alleles and drive helper and cytotoxic T cell responses in patients with Parkinson's disease.
Journal ArticleDOI
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Eric D. Hsi,Roxanne Steinle,Balaji Balasa,Susann Szmania,Aparna Draksharapu,Benny P. Shum,Mahrukh Huseni,David M. W. Powers,Amulya Nanisetti,Yin Zhang,Audie Rice,Anne van Abbema,Melanie Wong,Gao Liu,Fenghuang Zhan,Myles B.C. Dillon,Shihao Chen,Susan Rhodes,Franklin Fuh,Naoya Tsurushita,Shankar Kumar,Vladimir Vexler,John D. Shaughnessy,Bart Barlogie,Frits van Rhee,Mohamad A. Hussein,Daniel E. H. Afar,Marna Williams +27 more
TL;DR: It is suggested that HuLuc63 eliminates myeloma cells, at least in part, via NK-mediated ADCC and shows the therapeutic potential of targeting CS1 with Hu Luc63 for the treatment of multipleMyeloma.
Journal ArticleDOI
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
Yu-Tzu Tai,Myles B.C. Dillon,Weihua Song,Merav Leiba,Xian Feng Li,Peter Burger,Alfred Ian Lee,Klaus Podar,Teru Hideshima,Audie G. Rice,Anne van Abbema,Lynne Jesaitis,Ingrid Caras,Debbie A. Law,Edie Weller,Wanling Xie,Paul G. Richardson,Nikhil C. Munshi,Claire Mathiot,Hervé Avet-Loiseau,Daniel E. H. Afar,Kenneth C. Anderson +21 more
TL;DR: The functional significance of CS1 in MM is defined and the preclinical rationale for testing HuLuc63 in clinical trials is provided, either alone or in combination.
Journal ArticleDOI
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
Frits van Rhee,Susann Szmania,Myles B.C. Dillon,Anne van Abbema,Xin Li,Mary K. Stone,Tarun K. Garg,Jumei Shi,Amberly Moreno-Bost,Rui Yun,Balaji Balasa,Bishwa Ganguly,Debra Chao,Audie Rice,Fenghuang Zhan,John D. Shaughnessy,Bart Barlogie,Shmuel Yaccoby,Daniel E. H. Afar +18 more
TL;DR: It is shown that elotuzumab could induce patient-derived myeloma cell killing within the bone marrow microenvironment using a SCID-hu mouse model and that CS1 gene and cell surface protein expression persisted on myelomas collected after bortezomib administration.
Journal ArticleDOI
Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes.
Sinu Paul,Cecilia S. Lindestam Arlehamn,Thomas J. Scriba,Myles B.C. Dillon,Carla Oseroff,Denise Hinz,Denise M. McKinney,Sebastian Carrasco Pro,John Sidney,Bjoern Peters,Alessandro Sette +10 more
TL;DR: Using human immunogenicity data associated with sets of 15-mer peptides overlapping by 10 residues spanning over 30 different allergens and bacterial antigens, and HLA class II binding prediction tools from the Immune Epitope Database and Analysis Resource, a strategy to predict the top epitopes recognized by human populations was optimized.